A primary cell is a battery that is designed to be used once and discarded, and not recharged with electricity and reused like a secondary cell. In general, the electrochemical reaction occurring in the cell is not reversible, rendering the cell unrechargeable. 
            
            
            
         
     
    
        
                    
                                    
                
         
                
                    
                                        
                        
                    
                            - 
                    
                                                                    
                                    
                                        
    
    
    
        Immune checkpoint therapies targeting the CTLA-4 and PD-(L)1 pathways have been largely clinically disappointing for patients with prostate cancer. This can be attributed to the highly immun...
     
 
 
                                    
                                                                    
                                    
                                        
    
    
    
        One of the main challenges in cancer immunotherapy is the resistance to I-O therapies. Primary resistance can occur before treatment and acquired resistance can occur in patients who respond...
    
    
            
     
                                     
                                    
                                                                    
                                    
                                        
    
    
    
        1. Identify 3 barriers to immune cell response to cancer 2. List 3 approaches to overcome immunosuppressive barriers to bolster the immune response to cancer 3. Explain how fusion proteins c...
    
    
            
     
                                     
                                    
                                                                    
                                    
                                        
    
            
    
    
    
        DATE: June 2, 2020 TIME: 7:00am PT, 10:00am ET In just a few months COVID-19 has risen from a regional crisis to a global threat, and drug makers are now scrambling to develop vaccines aimed...
    
    
            
     
                                     
                                    
                                                                    
                                    
                                        
    
    
    
        Background: Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Despite recent advancements in the treatment of AML, approximately 50% of pat...
    
    
            
     
                                     
                                    
                                                                    
                                    
                                        
    
    
    
        Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...